Clinical trials: Cutaneous Squamous Cell Cancer
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers
- Conditions
- Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT05910827
- Testing
- HMBD-001, Docetaxel, Cetuximab
- Where
- 20 sites in Australia, Moldova and 3 more
- Volunteers
- 398 people
- Sponsor
- Hummingbird Bioscience
Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin
This is a Phase 1 open-label, multi-center, dose-escalation study to evaluate the safety, PK, anti-tumor activity, and pharmacodynamic effects of SL-172154 administered by intratumoral injection in subjects with cutaneous…
- Trial name
- NCT04502888
- Testing
- Drug: SL-172154
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- Shattuck Labs, Inc.
Non-small Cell Lung Cancer, Gastric Carcinoma
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are.
- Conditions
- Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma
- Trial name
- NCT04254107
- Testing
- SEA-TGT, sasanlimab, brentuximab vedotin
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 133 people
- Sponsor
- Seagen Inc.
Advanced Cutaneous Squamous Cell Carcinoma
Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
The purpose of this study is to evaluate the safety and efficacy of IBI318 (anti-PD-1/PD-L1) in adult participants with metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC), or unresectable locally advanced CSCC…
- Trial name
- NCT04611321
- Testing
- IBI318
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.